Dogwood Therapeutics DWTX Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's business segments — research and development expense?
- Dogwood Therapeutics (DWTX) reported business segments — research and development expense of $2.67M in Q1 2026.
- How has Dogwood Therapeutics's business segments — research and development expense changed year-over-year?
- Dogwood Therapeutics's business segments — research and development expense increased by 9.6% year-over-year, from $2.44M to $2.67M.
- What is the long-term trend for Dogwood Therapeutics's business segments — research and development expense?
- Over 2 years (2023 to 2025), Dogwood Therapeutics's business segments — research and development expense has grown at a 255.7% compound annual growth rate (CAGR), from $1.73M to $21.87M.
- What does business segments — research and development expense mean?
- The total aggregate expenditure dedicated to the discovery and development of new products or technologies. For development-stage companies, this is the primary indicator of the intensity and pace of the innovation pipeline.